PMID- 22621180
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20181201
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 38
IP  - 9
DP  - 2012 Sep
TI  - OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
PG  - 1497-505
LID - 10.1111/j.1524-4725.2012.02456.x [doi]
AB  - BACKGROUND: Few dosing data on onabotulinumtoxinA to treat hyperdynamic perioral 
      lines (POLs) are available. Studying onabotulinumtoxinA in controlled settings is 
      beneficial to treating a hyperfunctional orbicularis oris. OBJECTIVE: To compare 
      the dose-response relationship of two doses of onabotulinumtoxinA in hyperdynamic 
      POLs. METHODS: Female subjects (N = 60) received injections of onabotulinumtoxinA 
      at four sites totaling 7.5 U or 12.0 U. Subjects returned at weeks 2, 4, 8, 12, 
      16, and 20. POL severity and total lip satisfaction (TLS) were assessed at all 
      visits. RESULTS: Investigator-assessed POL severity was reduced through week 20 
      for 12.0 U (p < .01). POL reduction for 7.5 U persisted until week 16 (p < .05). 
      Responder rates did not differ until week 12 (12.0 U, 77%; 7.5 U, 36%; p = .003). 
      Subject-assessed TLS was improved (p < .05) at all time points for both groups 
      except at week 20 (12.0 U; p = .06). Most adverse events (AEs) were mild to 
      moderate in severity and typical for onabotulinumtoxinA treatment in the lips, 
      and the incidence was dose-dependent. CONCLUSION: OnabotulinumtoxinA provides 
      significant reductions in POL severity and high levels of subject satisfaction. 
      Lack of dose response and fewer AEs suggest that treatment of hyperdynamic POLs 
      with 7.5 U appears adequate for up to 16 weeks.
CI  - (c) 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley 
      Periodicals, Inc.
FAU - Cohen, Joel L
AU  - Cohen JL
AD  - AboutSkin Dermatology and DermSurgery, Englewood, CO 80113, USA. 
      jcohenderm@yahoo.com
FAU - Dayan, Steven H
AU  - Dayan SH
FAU - Cox, Sue Ellen
AU  - Cox SE
FAU - Yalamanchili, Ramana
AU  - Yalamanchili R
FAU - Tardie, Greg
AU  - Tardie G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120523
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Adult
MH  - Botulinum Toxins, Type A/*administration & dosage/adverse effects
MH  - Chi-Square Distribution
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Lip
MH  - Middle Aged
MH  - Neuromuscular Agents/*administration & dosage/adverse effects
MH  - Patient Satisfaction
MH  - Photography
MH  - Skin Aging/*drug effects
MH  - Statistics, Nonparametric
MH  - Time Factors
EDAT- 2012/05/25 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/05/25 06:00
PHST- 2012/05/25 06:00 [entrez]
PHST- 2012/05/25 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1111/j.1524-4725.2012.02456.x [doi]
PST - ppublish
SO  - Dermatol Surg. 2012 Sep;38(9):1497-505. doi: 10.1111/j.1524-4725.2012.02456.x. 
      Epub 2012 May 23.